Alx oncology provides corporate update and highlights key milestones in 2022

South san francisco, calif., jan. 10, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022.
ALXO Ratings Summary
ALXO Quant Ranking